Allogene Therapeutics, Inc. Q2 FY2026 earnings call

• Strategic Shift and Company Leadership

  • This marks Zachary Roberts' first quarterly call as CEO, building on the foundation laid by co-founder David Chang.
  • The company's 2024 strategic shift focuses on leveraging off-the-shelf allogeneic CAR-T's unique strengths (ready availability, consistent product quality independent of patient immune status, local treatment access) to fill unmet needs unaddressed by existing modalities, rather than positioning allogeneic CAR-T as a transitional stepping stone to other therapies.

• Alpha 3 Program (Semicell for MRD-positive first-line large B-cell lymphoma consolidation)

  • The Alpha 3 trial tests early intervention with off-the-shelf CAR-T in high-risk, MRD-positive patients after first-line treatment to prevent relapse, reduce toxicity compared to standard second-line and autologous CAR-T, and enable treatment in local community settings.
  • Interim futility analysis results showed Semicell drove rapid MRD clearance in a majority of patients, with zero treatment-related hospitalizations; most patients were managed entirely as outpatients, and successful delivery was achieved in community practices with no prior CAR-T experience.
  • The FDA granted RMAT and Fast Track designation for Semicell, acknowledging MRD positivity post-first-line treatment as an unmet medical need and validating the Alpha 3 strategy; RMAT enables more frequent, focused regulatory engagement to streamline development.
  • The company hit its 2026 target of 80+ active clinical sites in July, and now expects ~100 active sites by the end of 2026, with most in the U.S. and additional sites in Canada, Australia, and South Korea, driven by strong investigator interest post-interim data.

• Allo 316 Program (CD70-targeted allogeneic CAR-T for CD70 high renal cell carcinoma)

  • Traverse trial results were published in the Journal of Clinical Oncology, with the optimized regimen achieving a 31% confirmed overall response rate in this hard-to-treat solid tumor setting.
  • No responding patients had experienced disease progression at data cutoff, with follow-up ranging from 8 to over 18 months post-single dose; results are notable despite a small patient cohort and past safety challenges, and provide foundational evidence for the company's Dagger technology platform.

• Allo 329 Program (Resolution Trial for autoimmune disease)

  • Allo 329 was designed from the outset with the Dagger platform, and is engineered to avoid requiring standard chemotherapy-based lymphodepletion by targeting activated host T cells that drive allorejection, centered on patient needs.
  • Enrollment is progressing quickly across cohorts, dose levels, and lymphodepletion strategies even in a competitive field, and remains on track to deliver a clinical and translational update by the end of 2026.

Allogene Therapeutics is a clinical-stage biotech company focused on allogeneic CAR-T therapy, and no commercial product segment revenue results were disclosed in this Q2 2026 earning call. The transcript only covers progress across three clinical development programs, with no financial performance data for revenue-generating product segments reported.

• The interim EFS analysis for the Alpha 3 trial remains on track for mid-2027, with no adjustment to the original timeline despite accelerated site activation and enrollment progress.
• The company expects to provide program updates for Alpha 3 throughout 2027, including enrollment progress and potential data readouts, with timing guided by regulatory discussions and the Independent Data Monitoring Committee.
• A full clinical and translational data readout for the Allo 329 Resolution trial, including safety, efficacy, and translational findings across the 20 million, 40 million, and 80 million dose cohorts, is still expected in Q4 2026.
• The current target enrollment for the Alpha 3 trial remains 220 randomized patients, though the company will consider adding additional cohorts or exploring new nuances in the field if opportunities arise.

• Forward-looking statements regarding clinical trial progress, trial timelines, data outcomes, regulatory approvals, and commercial potential are subject to inherent risks and uncertainties, as outlined in Allogene's SEC disclosures.
• The Allo 316 program has faced notable safety challenges, and results are based on a small patient cohort; the company has not claimed success for allogeneic CAR-T in solid tumors and notes the field remains in early development.
• It is unlikely that the interim EFS analysis for Alpha 3 will achieve statistical significance without demonstrating overwhelming efficacy, due to the pre-specified alpha allocation between the interim and final analysis.
• Competitive developments from autologous CAR-T programs and in vivo CAR-T technologies may impact the Alpha 3 trial and commercial opportunity, though management believes its current positioning is well-protected.

Q: Why was an observational cohort of MRD-negative patients added to the Alpha 3 study, and what is its goal? / A: The cohort is intended to provide context for the trial's main results in randomized MRD-positive patients. Prospective comparison of outcomes between MRD-positive treated patients and MRD-negative control patients will allow further prospective validation of the MRD test itself.

Q: Could the Alpha 3 interim EFS analysis happen earlier than the previously guided mid-2027 timeline, given accelerated site activation? / A: Management is maintaining the original guidance for the analysis timing, and is only accelerating trial enrollment to hit the existing target as planned. No adjustments to the expected data availability timeline have been made at this time.

Q: What data can we expect from the Q4 2026 Allo 329 Resolution trial readout, and will the planned 20/40/80 million dose cohorts still be included? / A: The readout will include safety, efficacy, and translational data from all dosed cohorts through that point. The three planned 20 million, 40 million, and 80 million dose cohorts will all be included in the update, with any additional higher dose cohorts that are completed also added.

Q: How does Allogene view the competitive landscape, including ongoing frontline autologous CAR-T studies and recent in vivo CAR-T data? / A: Management believes Alpha 3's position as first-line consolidation for MRD-positive patients is well-protected, as no other program is explicitly targeting this space. Ongoing frontline autologous and bispecific programs have high toxicity and logistical complexity that will limit adoption to a small subset of patients at specialized centers, leaving the overall community MRD rate largely unchanged. Early in vivo CAR-T will likely first replace autologous CAR-T in relapsed settings, as community oncologists are not expected to adopt toxic in vivo viral delivery, leaving Alpha 3's accessible off-the-shelf model differentiated.